L'intérêt à découvert pour Battalion Oil donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Battalion Oil. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Battalion Oil (AMEX:BATL) Stock, Rapport sur les intérêts à découvert

Battalion Oil

Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.

Battalion Oil Corp

Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) has outperformed the market over the past 5 years by 19.18% on an annualized basis producing an average annual return of 33.3%. Currently, Fair Isaac has a market capitalization of $43.89 billion. 
Buying $100 In FICO: If an investor had bought $100 of FICO stock 5 years ago, it would be worth $427.36 today based on a price of $1803.05 for FICO at the time of writing.
<h3>Fair Isaac's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750171512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

FICO

Here's How Much You Would Have Made Owning Fair Isaac Stock In The Last 5 Years

Macro Economic Events

Politics

Global

Economics

General

Reuters Cites German Chancellor Merz Telling Broadcaster ARD "Expect Deal With U.S. In Tariff Dispute Before Summer's Over"

WIIM

Comstock Resources shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform and announced a $34 price target.

AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">myelodysplastic syndrome (HR-MDS)</a>.
MDS is a group of cancers in which the bone marrow doesn&#8217;t produce enough healthy blood cells.
The primary outcome measure is overall survival (OS). Key secondary outcome measures include a modified overall response (mOR) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45948002/abbvie-provides-update-on-verona-trial-for-newly-diagnosed-higher-risk-myelodysplastic-syndromes" rel="noreferrer noopener">and complete remission (CR)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45079377/abbvie-scores-fda-approval-for-its-blockbuster-drug-rinvoq-to-treat-type-of-arthritis" rel="noreferrer noopener">AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis</a>
The trial did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.
Results from the VERONA trial will be available in a future medical congress and/or publication.
The treating physician will inform any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials.&nbsp;
These data do not impact any currently approved indications for venetoclax.
In the first quarter, AbbVie reported Venclexta&#8217;s revenues were&nbsp;$665 million, <a target="_blank" href="https://www.benzinga.com/25/04/45011116/abbvie-q1-earnings-come-ahead-of-expectations-ceo-says-well-positioned-for-long-term" rel="noreferrer noopener">up 8.3% year over year (+12.3%)</a>.
Last week, the U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie&#8217;s Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45890526/fda-expands-abbvies-mavyret-label-to-include-pediatric-patients-with-hepatitis-c-infection" rel="noreferrer noopener">or with compensated cirrhosis.</a>
With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.
HCV is a highly infectious blood-borne disease affecting the liver.
<h2 class="wp-block-heading">AbbVie Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at AbbVie, an investor could make an assessment about a stock&#8217;s long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For AbbVie, the 200-day moving average sits at $188.78, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is below the current price of $189.54. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ABBV stock is trading lower by 1.47% to $188.06 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45946402/incytes-experimental-therapy-shows-platelet-normalization-and-safety-in-rare-blood-cancer-trials-across-doses" target="_blank" rel="noreferrer noopener">Incyte&#8217;s Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Large Cap

Health Care

Movers

ABBV

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and raises the price target from $8 to $9.

Price Target

Analyst Ratings

SAGE

Truist Securities Maintains Hold on Sage Therapeutics, Raises Price Target to $9

TMUS

T-Mobile shares are trading lower following a report indicating SoftBank plans to raise $4.9 billion through a share sale in the company.

Truist Securities analyst Michael Roxland maintains Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Buy and raises the price target from $237 to $239.

Truist Securities Maintains Buy on Packaging Corp of America, Raises Price Target to $239

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $305 to $280.

Truist Securities Maintains Hold on Humana, Lowers Price Target to $280

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.16% to 42,448.43 while the NASDAQ fell 0.35% to 19,633.04. The S&amp;P 500 also fell, dropping, 0.23% to 6,019.32.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45968628/wall-streets-most-accurate-analysts-weigh-in-on-3-financial-stocks-with-over-15-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 15% Dividend Yields</a>
Leading and Lagging Sectors Energy shares jumped by 1.4% on Tuesday.
In trading on Tuesday, health care stocks fell by 0.8%.
Top Headline
U.S. retail sales fell 0.9% month-over-month in May compared to a revised 0.1% decline in April and versus market estimates of a 0.7% fall.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares shot up 220% to $0.7219 after the company signed a binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 for gastroparesis.</li>
<li>Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) got a boost, surging 160% to $0.7990 after the company announced publication of its Phase 2 ibezapolstat study results in The Lancet.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares were also up, gaining 135% to $16.20 after the company received FDA Orphan Drug Designation for CER-1236 for the treatment of acute myeloid leukemia.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares dropped 56% to $0.1706 after the company announced the pricing of a $4.3 million public offering of 21.5 million shares at $0.20 per share.</li>
<li>Shares of Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were down 43% to $5.50 after GLJ Research downgraded the stock from Hold to Sell. Keybanc analyst Sophie Karp also downgraded Sunrun from Sector Weight to Underweight.</li>
<li>Solaredge Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) was down, falling 39% to $14.62 after GLJ Research downgraded the stock from Hold to Sell. Keybanc analyst Sophie Karp downgraded the stock from Sector Weight to Underweight.</li>
</ul>
Commodities In commodity news, oil traded up 2.1% to $73.30 while gold traded down 0.4% at $3,405.00.
Silver traded up 2% to $37.160 on Tuesday, while copper fell 0.7% to $4.8025.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.8%, while Spain's IBEX 35 Index dipped 1.2%. London's FTSE 100 fell 0.5%, Germany's DAX 40 declined 0.8% and France's CAC 40 fell 0.7% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei gaining 0.59%, Hong Kong's Hang Seng Index falling 0.34%, China's Shanghai Composite falling 0.04% and India's BSE Sensex falling 0.26%.
Economics
<ul class="wp-block-list">
<li>U.S. retail sales fell 0.9% month-over-month in May compared to a revised 0.1% decline in April and versus market estimates of a 0.7% fall.</li>
<li>U.S. import prices came in unchanged from the previous month in May, while export prices declined 0.9% month-over-month in May.</li>
<li>U.S. industrial production declined 0.2% in May, versus market estimates of a 0.1% gain.</li>
<li>The NAHB/Wells Fargo Housing Market Index declined two points to 32 for June, recording the lowest reading since December 2022.</li>
<li>U.S. business inventories came in flat month-over-month in April following a 0.1% gain in the previous month.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45970767/top-3-health-care-stocks-that-are-ticking-portfolio-bombs">Top 3 Health Care Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Markets

ACXP

CERO

PCSA

SDST

SEDG

US Stocks Lower; Retail Sales Decline In May

Canaccord Genuity analyst Whitney Ijem downgrades Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) from Buy to Hold and lowers the price target from $39 to $13.

Downgrades

VERV

Canaccord Genuity Downgrades Verve Therapeutics to Hold, Lowers Price Target to $13

PureCycle Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) shares are trading higher by 23.1% at $14.61 Tuesday morning following a strategic announcement poised to accelerate the company&#8217;s global footprint.
Investors are reacting positively to the company&#8217;s <a href="https://www.benzinga.com/pressreleases/25/06/ac45969126/purecycle-announces-300-million-capital-raise-outlines-growth-plan-for-one-billion-pounds-of-inst">plan</a> to achieve one billion pounds of installed recycling capacity by 2030 across the United States, Europe and Asia.
What To Know: PureCycle Technologies says this plan includes a $300 million capital raise, with binding agreements executed with new and existing investors, including names like Duquesne Family Office LLC and Samlyn Capital. This capital infusion directly supports PureCycle&#8217;s growth initiatives.
Read Also: <a href="https://www.benzinga.com/news/health-care/25/06/45973310/surgery-partners-rejects-bain-capitals-private-buyout-offer-will-remain-independent">Surgery Partners Rejects Bain Capital&#8217;s Private Buyout Offer, Will Remain Independent</a>
Adding to the positive momentum, PureCycle has <a href="https://www.benzinga.com/pressreleases/25/06/ac45969126/purecycle-announces-300-million-capital-raise-outlines-growth-plan-for-one-billion-pounds-of-inst">announced</a> a new partnership with IRPC Public Company Limited, Southeast Asia&#8217;s petrochemical leader, to construct a 130-million-pound polypropylene recycling facility in Thailand. 
This facility, leveraging IRPC&#8217;s existing infrastructure, is expected to commence construction in the latter half of 2025 and become operational by mid-2027. Further expansion includes a 130-million-pound line in Antwerp, projected for 2028, and a larger Gen 2 line in Augusta, Georgia, expected to be operational by 2029.
Key Stats: The company&#8217;s trading volume today stands at 4.5 million shares early Tuesday, significantly higher than its 100-day average volume of 2.915 million shares. Short interest in the stock remains high, with 48.812 million shares short, representing 45.47% of the float, according to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest">Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill</a>
<h2 class="wp-block-heading">How To Buy PCT Stock</h2>
By now you're likely curious about how to participate in the market for PureCycle Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, PCT has a 52-week high of $15.58 and a 52-week low of $4.50.

PureCycle Technologies (PCT) Stock Soars On $300M Raise & Global Expansion

JBLU

JetBlue shares are trading lower on a report suggesting the company will cut more flights and other costs, with break-even in 2025 is "unlikely" due to weaker travel demand.

Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) has outperformed the market over the past 15 years by 9.36% on an annualized basis producing an average annual return of 21.41%. Currently, Visa has a market capitalization of $683.84 billion. 
Buying $100 In V: If an investor had bought $100 of V stock 15 years ago, it would be worth $1,812.04 today based on a price of $356.79 for V at the time of writing.
<h3>Visa's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750170613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Truist Securities analyst Youssef Squali maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Buy and raises the price target from $55 to $60.

ETSY

Truist Securities Maintains Buy on Etsy, Raises Price Target to $60

ENPH

FSLR

Shares of solar stocks are trading lower after the US Senate Finance Committee unveiled its version of President Donald Trump's tax bill which slashed renewable energy incentives.

Truist Securities analyst Joon Lee initiates coverage on PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Buy rating and announces Price Target of $80.

Initiation

PTCT

Truist Securities Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $80

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) has released its updated&nbsp;Qwen3 family&nbsp;of&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence&nbsp;(AI) models</a>, which could signal the potential roll-out in China of machine-learning technology on Apple&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) devices.
This includes&nbsp;iPhones, iPads, and MacBooks, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3314772/alibaba-updates-open-source-qwen3-models-support-ai-deployment-apple-devices" rel="noreferrer noopener">reported</a> on Tuesday, citing a company tweet.
Open source gives the public access to a software program&#8217;s source code, allowing third-party developers to modify or share its design, fix broken links, or scale up its capabilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45840001/apples-wwdc-analyst-sees-ai-unveil-siri-revamp-and-alibaba-deal-as-catalyst-for-iphone-upgrade" rel="noreferrer noopener">Apple&#8217;s WWDC: Analyst Sees AI Unveil, Siri Revamp And Alibaba Deal As Catalyst For iPhone Upgrade</a>
Recently, Alibaba co-founder and Chair&nbsp;Joe Tsai&nbsp;said he opted to <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45925331/alibaba-co-founder-sees-open-source-qwen-driving-cloud-demand" rel="noreferrer noopener">open-source its</a> Qwen models, citing their potential to drive demand for&nbsp;AI&nbsp;applications and cloud computing.
Benchmark analyst&nbsp;Fawne Jiang&nbsp;mentioned Alibaba as a leading beneficiary of accelerated AI adoption in China and a top structural player in the sector.
This latest development reflects Apple&#8217;s efforts to expand the availability of its Apple Intelligence suite to mainland China. Under Chinese rules, any model part of Apple Intelligence would need regulatory approval for public release in the country.
Alibaba released the Qwen3 AI models for MLX via&nbsp;Hugging Face and Alibaba Cloud&#8217;s&nbsp;ModelScope&nbsp;site.
<h2 class="wp-block-heading">Why It Matters</h2>
Alibaba&nbsp;has committed at least&nbsp;380 billion yuan ($52 billion) in cloud computing and AI infrastructure over the next three years. Alibaba Cloud&nbsp;is China&#8217;s largest cloud service provider, with over one-third of the market.
Counterpoint <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45930835/iphone-sales-rebound-in-china-but-apples-next-move-could-be-risky" rel="noreferrer noopener">had highlighted how</a> the U.S. and Chinese markets dictated the iPhone&#8217;s prospects.
It is noteworthy that Counterpoint&nbsp;cut growth expectations&nbsp;for&nbsp;global smartphone shipments&nbsp;in 2025 to 1.9%, down from the prior 4.2%, citing the Trump administration&#8217;s tariffs. The firm also expects&nbsp;Apple and&nbsp;Samsung Electronics shipments to slow.
International Data Corporation&nbsp;(IDC)&nbsp;cut the 2025&nbsp;global smartphone shipment&nbsp;growth outlook to 0.6% from 2.3%.
IDC expects Apple&#8217;s&nbsp;smartphone&nbsp;shipments in China to fall by 1.9%&nbsp;in 2025.
Price Actions: BABA stock is up 0.18% at $116.17 at last check Tuesday. AAPL is down 0.34%.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45942472" target="_blank" rel="noreferrer noopener">Apple Opens iOS 26 Lock Screen Animation To Spotify And Other Third-Party Music Apps: Report</a></li>
</ul>
Photo by Poetra.RH via Shutterstock

Asia

Tech

Media

AAPL

BABA

Alibaba Updates LLMs To Power AI On Apple Devices In China

Wall Street&#8217;s bearish stance on the U.S. dollar has hit levels not seen in two decades, with fund managers overwhelmingly underweight the greenback as concerns mount over America&#8217;s fiscal trajectory and Donald <a href="https://www.benzinga.com/topic/donald-trump">Trump's conflicting trade policies.</a>
According to Bank of America&#8217;s June Global Fund Managers Survey, a net 37% of respondents said they are underweight the dollar—the most extreme underallocation since January 2005.
Bank of America&#8217;s chief investment strategist Michael Hartnett described the bearish sentiment as the "most extreme view" in this month's survey. Still, he warned that crowded trades often backfire. 
See Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45971228/retail-sales-slump-more-than-expected-as-tariff-fears-hit-spending">Retail Sales Slump More Than Expected As Tariff Fears Hit Spending </a>
"Biggest summer pain trade is long the buck," Hartnett said.
The U.S. dollar index — as closely tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) — has fallen by 12% since Trump&#8217;s inauguration day on January 20, 2025.
<h3 class="wp-block-heading">Investors Are Less Pessimistic On Growth</h3>
Despite the weak dollar outlook, global economic optimism has risen among fund managers. Since Trump paused reciprocal tariffs for 90 days and signaled willingness for trade agreements with China, global recession fears have plunged.
Just two months ago, 42% of investors surveyed expected a recession in the next 12 months. That figure has now flipped, with 36% saying a recession is "unlikely." 
Expectations for economic deterioration have dropped sharply, with only 46% forecasting a weaker global economy—down from a record-high 82% in April, marking the largest two-month swing since the 2024 election.
Conviction in a global economic "soft landing" rose to 66%, the highest since October 2024. In contrast, only 13% anticipate a "hard landing," a sharp drop from 49% in April. 
Meanwhile, expectations for a scenario where growth remains resilient without any meaningful slowdown—dubbed "no landing"—are rising, up to 16% from just 3% two months ago.
Most investors believe the final tariff rate the U.S. will impose on imports will remain modest. Only 1% see it exceeding 30%, while 77% anticipate a rate under 15%. The weighted average expected tariff is 13%, easing fears of a trade war-style disruption.
About 59% of fund managers say the Trump&#8217;s Big Beautiful Bill won't boost GDP growth, while a third see it as supportive. 
The deficit, already near 7% of GDP, is projected to worsen, with 81% forecasting a larger shortfall due to Senate provisions. Just 14% believe the bill will be self-financing.
&#8220;3 most contrarian trades based on Fund Manager Survey sentiment are&nbsp;long US&nbsp;dollar, short gold; long US, short EU stocks; long consumer, short banks,&#8221; Hartnett stated. 
<h3 class="wp-block-heading">Could Dollar Bearishness Signal A Turning Point?</h3>
Back in January 2005, when the dollar pessimism hit another extreme, the greenback had just come off a painful 33% drawdown from its July 2001 peak.
That fueled the start of a bullish dollar trend, which lasted one year.
The U.S. dollar index surged 11% between January and July 2005, extending its rally to a 14% gain by mid-November. It ultimately ended the year with a 13% advance.
The historical parallel with 2005 is hard to ignore. 
That year, bearish sentiment proved to be a powerful contrarian indicator, preceding a double-digit rebound in the greenback. 
With positioning once again heavily skewed against the dollar, traders may want to revisit that playbook. 
While structural issues like deficits and fiscal expansion loom large, near-term market pain could come from a sudden reversal higher in the U.S. currency.
Now Read
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/45971364/golds-glory-days-numbered-citi-predicts-shock-25-crash-by-2026-heres-why">Gold&#8217;s Glory Days Numbered? Citi Predicts Shock 25% Crash By 2026 — Here&#8217;s Why </a></li>
</ul>
Image: Shutterstock

Currency ETFs

Forex

Econ #s

ETFs

PowerShares DB US Dollar Index Bullish Fund

Everyone Now Hates The Dollar—Is That The Ultimate Buy Signal?

<a href="https://www.bloomberg.com/news/articles/2025-06-17/salesforce-increases-prices-as-it-promotes-new-ai-features?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-17/salesforce-increases-prices-as-it-promotes-new-ai-features?embedded-checkout=true</a>

'Salesforce Increases Prices as it Promotes New AI Features'- Bloomberg

Meme coin heavyweights Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) saw sharp daily losses as sentiment across the crypto market turned cautious. However, several on-chain indicators and trader insights continue to point to <a href="https://www.benzinga.com/money/dogecoin-vs-shiba-inu">long-term bullish potential</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1714</td>
<td>$25.7 billion</td>
<td>&nbsp;-3.2%</td>
<td>-11.2%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001175</td>
<td>$6.92 billion</td>
<td>-3.2%&nbsp;</td>
<td>-10%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001038</td>
<td>$4.4 billion</td>
<td>-8.2%&nbsp;</td>
<td>-20%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: In an X <a href="https://x.com/MaxBecauseBTC/status/1934634775538499998">post</a> on June 16, MaxBecauseBTC described Dogecoin as the "Bitcoin of meme coins," emphasizing its role as a trendsetter for the broader meme coin sector.
According to him, the DOGE/MEME.C-DOGE pair functions like BTC dominance in the meme ecosystem. A breakdown in this chart typically signals strength in smaller cap meme coins, potentially setting the stage for a sharp alt-meme rally.
Meanwhile, InvestingHaven flagged $0.17 as Dogecoin's key short-term support. Although the RSI indicates oversold conditions, weak momentum may keep prices range-bound. He sees a potential swing either up to $0.25 or down to $0.15, depending on whether support holds.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> coin is holding near $0.17 after a 16% weekly drop. RSI is oversold, but weak momentum clouds the outlook &#8211; $0.17 is key short-term support &#8211; Price is driven more by sentiment than utility<a href="https://twitter.com/hashtag/DOGE?src=hash&amp;ref_src=twsrc%5Etfw">#DOGE</a> may swing to $0.25 or $0.15. <a href="https://t.co/7Jx3559WYj">pic.twitter.com/7Jx3559WYj</a>
&mdash; InvestingHaven (@InvestingHaven) <a href="https://twitter.com/InvestingHaven/status/1934587954481275249?ref_src=twsrc%5Etfw">June 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
MrHans, an analyst on TradingView, <a href="https://www.tradingview.com/chart/SHIBUSDT/QR2TqSe6-Shiba-Inu-next-chapter/">noted</a> that Shiba Inu is hovering near key support, and if it holds, a reversal toward $0.000021–$0.000024 is possible. However, any breakdown below $0.00001054 would invalidate the bullish setup.
Statistics: Shiba Inu burn rate surged 725% in 24 hours, with 17.7 million SHIB destroyed. One large burn eliminated 14.3 million SHIB in a single transaction. The seven-day burn rate has now jumped 1,501.2%, suggesting rising community activity and reduced supply.
Shibariumscan data shows daily transactions spiked to 4.57 million as of June 16 compared to 4.51 million as of June 15.
IntoTheBlock data shows Shiba Inu's large transaction volume expanded 1,700.5% in a single day while daily active addresses grew by 3.3%. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45959960/bitcoin-ethereum-xrp-dogecoin-extend-rally-hold-above-108450-well-target-all-time-highs">Bitcoin, Ethereum, XRP, Dogecoin Extend Rally: &#8216;Hold Above $108,450 We&#8217;ll Target All-Time Highs&#8217;</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

DOGE

Dogecoin, Shiba Inu Dip 3% In A Day - Is a Meme Coin Rally Still Brewing?

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DO, SRCL, BATL, SGE on Behalf of Shareholders

Earnings

Battalion Oil Corporation Announces Second Quarter 2024 Financial and Operating Results

Battalion Oil Corporation Announces Amendment to Merger Agreement with Fury Resources, Inc.

Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements

Battalion Oil Corporation Announces Third Quarter 2024 Financial and Operating Results

Battalion Oil Corporation Announces Termination of Merger Agreement with Fury Resources, Inc. and Provides Operations Update

Battalion Oil Corporation Announces Fourth Quarter 2024 Financial and Operating Results

Battalion Oil Corporation Announces First Quarter 2025 Financial and Operating Results

Comments

Battalion Oil

Intérêt court

Battalion Oil (AMEX:BATL) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL